While targeting RNR holds therapeutic promise, there are challenges. One major challenge is the development of resistance to RNR inhibitors. Cancer cells can develop compensatory mechanisms to bypass the inhibited RNR pathway, thereby maintaining their proliferative capacity. Additionally, because RNR is essential for normal cell functions, its inhibition can also affect healthy, dividing cells, leading to side effects.
